I agree 100%.It's a matter of patience. The valuation will catch up if the Nash program is confirmed with clinical data. As usual analysts don't care because there is no money involved for them.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.